JP2024069234A5 - - Google Patents
Info
- Publication number
- JP2024069234A5 JP2024069234A5 JP2024023383A JP2024023383A JP2024069234A5 JP 2024069234 A5 JP2024069234 A5 JP 2024069234A5 JP 2024023383 A JP2024023383 A JP 2024023383A JP 2024023383 A JP2024023383 A JP 2024023383A JP 2024069234 A5 JP2024069234 A5 JP 2024069234A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- peg
- conjugate
- asparaginase
- asp
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762592982P | 2017-11-30 | 2017-11-30 | |
| US62/592,982 | 2017-11-30 | ||
| US201862625078P | 2018-02-01 | 2018-02-01 | |
| US62/625,078 | 2018-02-01 | ||
| US201862631142P | 2018-02-15 | 2018-02-15 | |
| US62/631,142 | 2018-02-15 | ||
| US201862673075P | 2018-05-17 | 2018-05-17 | |
| US62/673,075 | 2018-05-17 | ||
| PCT/US2018/063448 WO2019109018A1 (en) | 2017-11-30 | 2018-11-30 | Methods of treatment with asparaginase |
| JP2020548883A JP2021505661A (ja) | 2017-11-30 | 2018-11-30 | アスパラギナーゼを用いた治療法 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548883A Division JP2021505661A (ja) | 2017-11-30 | 2018-11-30 | アスパラギナーゼを用いた治療法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024069234A JP2024069234A (ja) | 2024-05-21 |
| JP2024069234A5 true JP2024069234A5 (https=) | 2025-10-02 |
Family
ID=66664263
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548883A Pending JP2021505661A (ja) | 2017-11-30 | 2018-11-30 | アスパラギナーゼを用いた治療法 |
| JP2024023383A Pending JP2024069234A (ja) | 2017-11-30 | 2024-02-20 | アスパラギナーゼを用いた治療法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548883A Pending JP2021505661A (ja) | 2017-11-30 | 2018-11-30 | アスパラギナーゼを用いた治療法 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230173042A1 (https=) |
| EP (1) | EP3716997A4 (https=) |
| JP (2) | JP2021505661A (https=) |
| KR (2) | KR20200119234A (https=) |
| CN (1) | CN111818937A (https=) |
| AU (2) | AU2018375183B2 (https=) |
| BR (1) | BR112020010976A2 (https=) |
| CA (2) | CA3083499C (https=) |
| IL (1) | IL274865B2 (https=) |
| MX (1) | MX2020005567A (https=) |
| SG (1) | SG11202004965RA (https=) |
| WO (1) | WO2019109018A1 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11504347B1 (en) | 2016-07-22 | 2022-11-22 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11986451B1 (en) | 2016-07-22 | 2024-05-21 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US12478604B1 (en) | 2016-07-22 | 2025-11-25 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602512B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| UY37341A (es) | 2016-07-22 | 2017-11-30 | Flamel Ireland Ltd | Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada |
| US12186296B1 (en) | 2016-07-22 | 2025-01-07 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| US11602513B1 (en) | 2016-07-22 | 2023-03-14 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| CN113473980A (zh) | 2019-03-01 | 2021-10-01 | 弗拉梅尔爱尔兰有限公司 | 在进食状态下具有改善的药代动力学的γ-羟基丁酸酯组合物 |
| GB201912020D0 (en) * | 2019-08-21 | 2019-10-02 | Porton Biopharma Ltd | Therapeutic Conjugate |
| JP2022553399A (ja) * | 2019-10-25 | 2022-12-22 | ジャズ ファーマシューティカルズ アイルランド リミテッド | 組換えｌ－アスパラギナーゼ |
| WO2022211829A1 (en) | 2021-03-30 | 2022-10-06 | Jazz Pharmaceuticals Ireland Ltd. | Dosing of recombinant l-asparaginase |
| CN117377494A (zh) * | 2021-04-06 | 2024-01-09 | 爵士制药爱尔兰有限公司 | L-天冬酰胺酶的调配物 |
| US11583510B1 (en) | 2022-02-07 | 2023-02-21 | Flamel Ireland Limited | Methods of administering gamma hydroxybutyrate formulations after a high-fat meal |
| US11779557B1 (en) | 2022-02-07 | 2023-10-10 | Flamel Ireland Limited | Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics |
| WO2024015529A2 (en) | 2022-07-14 | 2024-01-18 | Jazz Pharmaceuticals Ireland Ltd. | Combination therapies involving l-asparaginase |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002044360A2 (en) * | 2000-11-28 | 2002-06-06 | Phoenix Pharmacologics, Inc. | Modified arginine deiminase |
| CN1360049A (zh) * | 2000-12-20 | 2002-07-24 | 上海博德基因开发有限公司 | 一种新的多肽——人l－天冬酰胺酶24.53和编码这种多肽的多核苷酸 |
| US7985548B2 (en) * | 2006-03-03 | 2011-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Materials and methods directed to asparagine synthetase and asparaginase therapies |
| ITMI20060612A1 (it) * | 2006-03-30 | 2007-09-30 | Keryos Spa | New activaded poly-ethylene glycols-and related polymers and their applications |
| WO2011003633A1 (en) * | 2009-07-06 | 2011-01-13 | Alize Pharma Ii | Pegylated l-asparaginase |
| HK1204578A1 (en) * | 2012-03-21 | 2015-11-27 | Erytech Pharma | Medicament for the treatment of acute myeloid leukemia (aml) |
| CN105802948B (zh) * | 2014-12-29 | 2020-06-09 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇定点修饰的门冬酰胺酶及其制备方法与应用 |
| CN105802946B (zh) * | 2014-12-29 | 2025-08-22 | 江苏众红生物工程创药研究院有限公司 | 聚乙二醇化的门冬酰胺酶及其应用 |
| EP3535386A4 (en) * | 2016-11-04 | 2020-04-15 | Georgia State University Research Foundation, Inc. | ENDOTOXIN-FREE ASPARAGINASE |
| GB201919219D0 (en) * | 2019-12-23 | 2020-02-05 | Otsuka Pharma Co Ltd | Cancer biomarkers |
-
2018
- 2018-11-30 JP JP2020548883A patent/JP2021505661A/ja active Pending
- 2018-11-30 KR KR1020207018920A patent/KR20200119234A/ko not_active Ceased
- 2018-11-30 KR KR1020257018693A patent/KR20250086810A/ko active Pending
- 2018-11-30 CA CA3083499A patent/CA3083499C/en active Active
- 2018-11-30 SG SG11202004965RA patent/SG11202004965RA/en unknown
- 2018-11-30 MX MX2020005567A patent/MX2020005567A/es unknown
- 2018-11-30 CN CN201880084869.5A patent/CN111818937A/zh active Pending
- 2018-11-30 IL IL274865A patent/IL274865B2/en unknown
- 2018-11-30 WO PCT/US2018/063448 patent/WO2019109018A1/en not_active Ceased
- 2018-11-30 AU AU2018375183A patent/AU2018375183B2/en active Active
- 2018-11-30 EP EP18884437.7A patent/EP3716997A4/en active Pending
- 2018-11-30 BR BR112020010976-2A patent/BR112020010976A2/pt unknown
- 2018-11-30 US US16/767,920 patent/US20230173042A1/en active Pending
- 2018-11-30 CA CA3240356A patent/CA3240356A1/en active Pending
-
2024
- 2024-02-20 JP JP2024023383A patent/JP2024069234A/ja active Pending
- 2024-12-11 AU AU2024278286A patent/AU2024278286A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024069234A5 (https=) | ||
| JP2021505661A5 (https=) | ||
| Pasut et al. | PEG conjugates in clinical development or use as anticancer agents: an overview | |
| AU2005314468B2 (en) | Combination of immuno gene therapy and chemotherapy for treatment of cancer and hyperproliferative diseases | |
| US10428114B2 (en) | Type polypeptide targeting tumours | |
| KR101394768B1 (ko) | 캄토테신-세포 투과 펩티드 결합체 및 이를 포함하는 약학 조성물 | |
| JP2012532185A5 (https=) | ||
| TW200817369A (en) | Preparation of polymer conjugates of therapeutic, agricultural and food additive compounds | |
| JP2020535171A (ja) | 去勢抵抗性前立腺癌 | |
| IL293553A (en) | Conjugated compounds that bind sortilin, preparations and uses thereof for the treatment of cancer | |
| WO2025061123A1 (zh) | 治疗非霍奇金淋巴瘤的药物组合及其用途 | |
| WO2013067767A1 (zh) | 聚乙二醇-氨基酸寡肽-依诺替康药物结合物及其药物组合物 | |
| JP2022552841A (ja) | ポリマー薬物送達コンジュゲートならびにそれを作製および使用する方法 | |
| EP4691495A1 (en) | Use of drug combination containing anti-cd20 antibody-drug conjugate in preparation of drug for treating nhl | |
| WO2009096245A1 (ja) | 医薬組成物又は組合せ剤 | |
| KR102314558B1 (ko) | 베네토클락스의 수용성 고분자 유도체 | |
| JP2021520344A5 (https=) | ||
| CN112533605A (zh) | 用于治疗癌症的组合疗法 | |
| Gundecha et al. | A review on impact of pegylation on biopharmaceuticals | |
| JP2015500836A5 (https=) | ||
| WO2025261276A1 (zh) | 含抗cd20抗体药物偶联物的药物组合及其治疗非霍奇金淋巴瘤的用途 | |
| Dashtipoura et al. | Polymeric micelles in TKIs’ delivery for cancer treatment | |
| Maciel | Metallodendrimers as HIV antiviral and anticancer agents | |
| WO2025056070A1 (zh) | 一种治疗肿瘤的组合疗法及其应用 | |
| AU2002364165B2 (en) | Process for affecting neurologic progression |